Sorbilact (sorbitol) solution for infusions 200 ml. vial


Manufacturer: Ukraine

To reduce intoxication due to the hyperosmolarity of the solution, improve microcirculation, correct the acid-base condition, improve hemodynamics in: traumatic, surgical, hemolytic and burn shock; peritonitis and bowel obstruction (pre- and postoperative period); acute renal failure of different etiology; sepsis; cholecystitis; various diseases of the liver (hepatitis, liver dystrophy, hepatic coma); increased intracranial pressure in the case of cerebral edema.



Sorbilact (sorbitol) solution for infusions 200 ml. vial


active ingredients: 1 ml of solution contains: sorbitol 200 mg; sodium lactate (in terms of 100% substance) 19 mg; sodium chloride 6 mg; calcium chloride dihydrate (in terms of calcium chloride) 0.1 mg; potassium chloride 0.3 mg; magnesium chloride hexahydrate (in terms of magnesium chloride) 0.2 mg;

excipients: water for injection.

Dosage form

Solution for infusion.

Basic physical and chemical properties: transparent colorless liquid; theoretical osmolarity – 1658 mOsmol / l; pH 6.00-7.60; ionic composition: 1 liter of the drug contains: Na + – 272.20 mmol;
K+ – 4.02 mmol; Ca++ – 0.90 mmol; Mg++ – 2.10 mmol; Cl- – 112.69 mmol; Lac- – 169.55 mmol.

Pharmacological group

Solutions affecting the electrolyte balance. Electrolytes in combination with other drugs.
ATX code B05B B04.

Pharmacological properties

This drug belongs to the means that affect the electrolyte balance.
The components of the drug have a pronounced anti-shock, energy, detoxification, alkaline, diuretic effect and stimulate intestinal motility. The solution is hypertonic and stimulates intestinal smooth muscle. In hepatocytes, the drug is converted into fructose, which, in turn, is metabolized into glucose, and then into glycogen.
The ingredients of the medicine are used by the body for urgent energy needs. The drug normalizes osmotic pressure. It is quickly included in the metabolism and undergoes transformation in the liver.


The drug Sorbilact solution is used in the following cases:

  • reduction of intoxication due to the hyperosmolarity of the solution;
  • improvement of microcirculation;
  • correction of the acid-base state;
  • improvement of hemodynamics in: traumatic, surgical, hemolytic and burn shock;
  • with peritonitis and intestinal obstruction (in the pre- and postoperative period);
  • with acute renal failure of various etiologies and sepsis;
  • with cholecystitis;
  • with various liver diseases (hepatitis, liver dystrophy, hepatic coma);
  • with increased intracranial pressure in case of cerebral edema.


The drug Sorbilact solution in question is contraindicated for use in cases where the patient has severe hypersensitivity (allergy) to the main or one of the auxiliary components.
The drug is contraindicated in the following cases:

  • alkalosis;
  • dehydration;
  • in cases where the infusion of large volumes of fluid is contraindicated (cerebral hemorrhage, thromboembolism, cardiovascular decompensation, grade III arterial hypertension, end-stage renal failure, pulmonary edema, decompensated heart defects, anuria, oliguria).

The drug is not used in pediatrics.

Application during pregnancy and lactation

This drug is contraindicated for pregnant women – only under strict indications determined by the attending physician.
If you need to take the drug during breastfeeding, you should stop lactation.

Method of administration and dosage

Sorbilact solution is administered to adults intravenously at a rate of 40-60 drops/min.

If necessary, jet administration of the drug after the test is allowed by drip injection at a rate of 30 drops / min. After the introduction of 15 drops, the use of the drug should be discontinued, and after 3 minutes, if there is no reaction, Sorbilact should be administered by jet.

For traumatic, burn, postoperative and hemolytic shocks, adults should be given 200-600 ml (3-10 ml/kg of body weight) once and 200-400 ml again, first by jet, then by drip. For liver diseases, adults should be administered at a dose of 200 ml (3.5 ml/kg of body weight) daily or every other day.

In acute renal failure, adults should be administered in a single dose of 200-400 ml
(2.5-6.5 ml / kg of body weight) drip or jet (again after 8-12 hours at a dose of 200 ml).

For the prevention of postoperative intestinal paresis, adults should be administered in a single dose of 150-300 ml (2.5-5 ml / kg of body weight) drip; Possible repeat infusions
200 ml of the drug every 12 hours during the first 2-3 days after surgery. For the treatment of postoperative paresis in adults, administer at a dose of 200-400 ml
(3.5-6.5 ml / kg of body weight) drip every 8 hours until intestinal motility is normalized. With cerebral edema, adults first bolus, and then drip
(60-80 drops per minute) at a dose of 5-10 ml/kg of body weight. With significant dehydration, intravenous infusions of Sorbilact should be carried out only by drip (no more than
200 ml of solution per day).


Data on the experience of use in children is not enough.


In case of an overdose, the following phenomena are possible:

  • alkalosis;
  • dehydration;
  • tachycardia;
  • increased blood pressure;
  • dyspnea;
  • headache;
  • abdominal pain.

Side effects

The drug is usually well tolerated when used in the recommended doses.
The following phenomena can be observed as side effects:

  • anaphylactoid reactions, angioedema, hyperthermia;
  • increase or decrease in blood pressure, tachycardia, shortness of breath, acrocyanosis;
  • tremor, headache, dizziness, general weakness;
  • skin rash, hives, itching;
  • abdominal pain, nausea, vomiting;
  • changes at the injection site, including pain and burning.